Yufeng Li, PhD, is currently Executive Director of Clinical Development at Qilu Pharma, based in Philadelphia, PA.
Yufeng graduated from Shanghai Jiao Tong University, and obtained PhD training at UT MD Anderson Cancer Center at Houston, focusing on cancer immunology and immunotherapy. Subsequently, he spent many years at GSK to discover and develop medicines for cancer patients. Prior to Qilu, Yufeng has also served China biotech companies (Ascentage and Transcenta) to oversee their US and global clinical programs.
Yufeng is active for community based volunteer activities, including serving important roles in organizations such as Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP). He has established the Pharma360° training program.